SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema
Clare Bailey, Marion Ronit Munk, Varun Chaudhary, Clemens Lange et autres
The PHOTON Phase 2/3 trial demonstrated the efficacy and safety of intravitreal aflibercept 8 mg in the treatment of diabetic macular oedema (DME) [ 1 ]. SPECTRUM is a global study evaluating aflibercept 8 mg treatment of DME and neovascular age-related macular …
gb, us, ch, ca, de, it, au, dk, fi, fr (code pays fourni par la source)